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The synthesis and enantiomeric features of 2-hydroxymethyl-
-tetrahydro-oxazolo[3,2-c]pyrimidine-5,7-(4H,6H)-diones (V) are.
described. The diazomethane methylation of these bicyclic com-
pounds afforded 2-hydroxymethyl-6-methyl-tetrahydro-oxazolo-
-[3,2-c]pyrimidine-5,7-(4H,6H)-diones (R)-(XXII) and (S)-(XXII),
respectively. For the synthesis of (R)-V and (S)-V the respective
5-bromo-1-(2,3-dihydroxypropyl)uracil (R)-(XVII) and (S)-(XVII)
were treated with KCN in DMF. The intermediate (R,S)-6-cyano-
-1-(2,3-dihydroxypropyl)uracil (XI) was shown to undergo the
anti-cyclisation yielding (R,S)-V if heated in DMSO at 40°c.
The bio-transformations of 1-allyl-6-chloro-3,5-diethyluraciP (AClU, I), a
drug for the external treatment of viral infections, and 6-chloro-3,5-diethyl-
-1-propyluraciI2 (II) possessing similar activities yielded 6,8-diethyl-2-hydro-
xymethyP(III) and 6,8-diethyl-2-methyP (IV) tetrahydro-oxazolo[3,2-c]-pyri-
midine-5,7-(4H,6H)-dione, respectively, as major metabolites. In order to shed
light on these transformations (Scheme 1), consisting of 2',3'-epoxide- [A]
and 2',3'-dihydroxypropyl- [E] uracil as intermediates for the formation of
metabolite III and 2'-hydroxypropyl-uracil [Cl as the intermediate for the
formation of the metabolite IV, our search was directed towards the synthesis
and enantiomeric features of thehitherto unknown 2-hydroxymethyl-tetra-
hydro-oxazoIo[3,2-c]pyrimidine-5,7-(4H,6H)-diones (V).
Sulphonylated derivatives of. (R,S)-1-(2,3-dihydroxypropyl)-uraciI4 (VI)
and its thymine analogue- (VII) underwent the syn-cyclisations to give the
respective (R,S)-2-hydroxymethyl-2,3-dihydro- (VIlI) and (R,S)-2-hydroxyme-
thyl-2,3-dihydro-6-methyl (IX)-oxazolo-7H-[3,2-a]pirimidin-7-one (Scheme 2)
on a route analogous the naturaI pyrimidine nucleosides. Attempting also to
generalize the anti-cyclisation reactions, applied in uridine series, by a possible
enhancement of the preponderantIy anti-oriented pentofuranosyl moietieso-s
and suitably halogenated? agIycones, we studied the analogous reaction se-
quence for the properly activated uracil analogue VI.
Reaction sequences for the synthesis of C(6), O-C(5') cyclouridine and
C(6), O-C(5') cyclocytidine'v-'! provided reagents and conditions (KCN in DMF
at room temperature) for the regioselective anti-cyclisation of (R,S)-5-bromo-
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-1-(2,3-dihydroxypropy l)uracil (X) into (R,S)-2-hydroxymethy 1-tetrahydro-oxa-
zolo[3,2-c]pyrimidine-5,7-(4H,6H)-dione (V). This C(6), O-C(2') cyclisation most
probably proceeded via the intermediate (R,S)-6-cyano-l-(2,3-dihydroxypro-
pyl)uracil (XI) by a mechanistic approach described for the formation of
C(6), O-C(5') cyclocytidine derivative'v-P. Therefore, (R,S)-6-cyano-l-(2,3-0-
-isopropylidene-2,3-dihydroxypropyl)uracil (XII) (Scheme 2) was prepared by
a cyanation (NaCN in DMF at room temperature) reaction of (R,S)-5-bromo-l-
-(2,3-0-isopropylidene-2,3-dihydroxypropyl)uracil (XIII) , the latter being pre-
pared from 5-bromouracil and the suitably activated glycerol derivative'",
The hydrolysis of isopropylidene derivative XII in 80 % AcOH at room
temperature yielded (R,S)-6-cyano-l-(2,3-dihydroxypropyl)uracil (XI) (970/0),
which indeed underwent anti-cyclisation into the bicyclic compound V. This
reaction proceeded under standard conditions (t-BuOK in DMF at room tem-
perature) but also in much higher yields when dissolved in DMSO and heated
at 40°C. These intramolecular transformations via an attack of the C(2')-
-hydroxy group at the C(6)-cyano position (possibly by a C(5), C(6)-addition-
-dehydrobromination mechanism), remains to be elaborated. Work is in pro-
gress, particularly on the synthesis of the deuterated and enantiomeric com-
pounds.
For our synthesis of the enantiomeric 2-hydroxymethyl-tetrahydro-oxa-
zolo[3,2-c]pyrimidine-5,7-(4H,6H)-diones (V) (Scheme 3) (S)-I-(2,3-0-isopropyli-
dene-2,3-dihydroxypropyl)-uracil13,14, [a]n23- 38° (c 2.5, CHC13), was firstly de-
blocked in boiling 800/0 AcOH to give (S)-I-(2,3-dihydroxypropyl)uracil (S)-VI),
[a]n25- 76° (c 1, EtOH) (Lit. 15 [a]n25 - 22.3° (c 1, H20» (Scheme 3). The
tritylation of the latter and subsequent mesylation of the resulting (S)-I-(2-
-hydroxy-3-trityloxypropyl)-uracil (S)-(XIV), [a]n23.5- 22° (c 1, EtOH), furni-
shed (S)-I-(2-mesyloxy-3-trityloxypropyl)uracil (S)-(XV), [a]n26 - 36° (c 2,
EtOH). The C(2'), O-C(2) cyclisation, accompanied with an inversion of the
C(2') conftguratlon'<" of the latter by treatment with 1,8-diazabicyclo[5.4.0]-
undec-7-ene in DMF, afforded (R)-2,3-dihydro-2-trityloxymethyl-oxazolo-7H-
-[3,2-a]-pyrimidin-7-one (R)-(XVI), [a]n20 + 16° (c 2, CHCh) in 960/0 yield. The
bicyclic compound (R)-XVI was finally converted into (R)--I-(2,3-dihydroxy-
propyl)uracil (R)-(VI), [a]n26 + 76° (c 1, EtOH), by a treatment with boiling
80% AcOH. Besides detritylation, this transformation involved the stereo-
controlled oxazolo ring opening through a possible intermediate C(2)-oxonium
ion and C(2)-OC(2') bond cleavage. The enantiomeric purity of the thus
obtained (R)-I-(2,3-dihydroxypropyl)uracil (R)-(VI) was confirmed by an un am-
bigous synthesis-! using methyl 5-(uracil-l-yl)-5-deoxy-2,3-0-isopropylidene-~-
-n-ribofuranoside-" as the starting material.
Decisive experiments, correlating the (R)- and (S)-configuration of (+)-
and (-)-I-(2,3-dihydroxypropyl)uracil (VI), were in the conditions effecting
anti-cyclisations. The diols (R)-VI and (S)-YI, dissolved in EtOH, were pre-
cedingly brominated into the respective 5-bromo-l-(2,3-dihydroxypropyl)uracil
(R)-(XVII) and (S)-(XVII) (Scheme 3). It is worth noting that the interactions
of 5-bromouracil with (R,S)-I-O-p-tolylsulphonyl-2,3-0-isopropylidene-glycero1
by means of NaH in DMF13 yielded (R,S)-5-bromo-l-(2,3-0-isopropylidene-
-oxypropyI)uracil (XIII) in higher yields than the interactions of uracil itself.
Since the C(6), O-C(2') cyclisations of the enantiomeric bromo-compounds
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(R)-XVII and (S)-XVII by the respective treatments with KCN in DMF pro-
ceeded via a series of transformations in the pyrimidine part of mclecules,
retentions of configurations at the C(2')-chira1 centre should be expected.
Therefore, the configurationa1 feature of (R)-2-hydroxymethy1-tetrahydro-oxa-
zolo[3,2-clpyrimidine-5,7-(4H,6H)-dione (R)-(V), [alD26 -13° (c 2, EtOH), obta-
ined from (R)-XVII, should correspond to L-g1ycero enantiomer (Scheme 3) and
(S)-2-hydroxymethy 1-tetrahydro-oxazo1o [3,2-c]pyrimidine-5, 7-(4H,6H)-dione
(S)-(V), [alD23+ 12° (c 2, EtOH), being derived from the n-glycero structure'",
to n-glycero enantiomer.
Our study of the stereochemistry re1ated to the bio-transformations of
AC1U (I) and here achived synthesis of the enantiomeric ž-hydroxymethyl-
-tetrahydro-oxazo1o[3,2-c]pyrimidine-5,7-(4H,6H)-diones (R)-(V) and (S)-(V) im-
proved the synthetic procedure for the bio1ogically interesting anti-cyclisations,
However, all attempted anti-cyclisations of (R,S)-5-bromo-l-(2,3-dihydroxy-
propy1)-3-methyl-uracil (XVIII) (Scheme 2) failed. The N(3)-methy1ated com-
pound XVIII was prepared from (R,S)-I-(2,3-0-isopropylidene-2,3-dihydroxy-
propyljuracil+ (XIX) in areaction with etherea1 diazomethane, followed by the
hydrolysis of the resulting (R,S)-I-(2,3-0-isopropylidene-2,3-dihydroxypropy1)-
-3-methyluracil (XX) in boi1ing 80% AcOH, and bromination of. the thus
obtained (R,S)-I-(2,3-dihydroxypropy1)-3-methy1uraci1 (XX!).
Methylation of the preformed bicyclic compound V gave (R,S)-2-hydroxy-
methy 1-6-methy 1-tetrahydro-oxazolo [3,2-c1pyrimidine-5, 7-(4H,6H)-dione (XXII)
(Scheme 1) by treatment with ethereal diazomethane. Similar methylations
of (R)- and (S)-2-hydroxymethy1-tetrahydro-oxazolo [3,2-c[pyrimidine-S, 7-(4H,-
6H)-diones (R)-(V) and (S)-(V) (Scheme 3) afforded 2-hydroxymethyl-6-methy1-
-tetrahydro-oxazo1o[3,2-clpyrimidine-5, 7-(4H,-6H)-diones (R)-(XXII), [alD22.5-
- 49.5° (c 1, MeOH) and (S)-(XXII), [alD23+ 49.9° (c 1, MeOH), respective1y,
in high yie1ds.
EXPERIMENTAL
Melting points, uncorrected, were taken with a Kofler hot-stage apparatus.
IR spectra were determined for potassium bromide pellets on a Perkin Elmer 297
spectrophotometer; UV spectra for solutions in 95% EtOH, unless otherwise stated,
on a Perkin-Elmer 124spectrophotometer; tH-NMR spectra for solutions in DMSO-d6,
unless otherwise stated, on a II JEOL FX90Q" spectrometer operating at 89.55 MHz
with tetramethylsilane as internal standard. 13C-NMRspectra were measured for
solutions in CDC13on a "JEOL FX90Q" spectrometer operating at 22.5 MHz. Multi-
plicities s, d, t, and q refer to off-resonance decoupled spectra. Optical rotations
were measured in 95% EtOH, unless otherwise stated, using a Zeiss-Winkler
179707apparatus. The silica gel (Merck, HF254type 60) for TLC and preparative
TLC was activated at 1100C for 60 min. The products were developed in ethyl-
acetate-isopropanol-water (75: 16 :9), and recovered from TLC chromatographic
plates with 95010EtOH, unless otherwise stated. The products were rendered visible
by UV illumination or iodine vapour.
(R,S)-5-Bromo-l-(2,3-dihydroxypropyl)uracil (X)
To a solution of (R,S)-1-(2,3-dihydroxypropyl)uracil (VI) (300 mg, 1.6 mmol)
in anhydrous EtOH (75 ml), a solution of bromine (0.17 ml, 3.1 mmol) in CH2Cl2
(24 ml) was added dropwise. The solution was then stirred at room temperature
for 2 h, the solvent removed under reduced pressure, and the residue recrystallized
from MeOH. It yielded 365 mg (81010),m. p. 208--2100C, RF ca. 0.71.
Anal. C7H9BrN204 (265.08)calc'd.: C 31.71;H 3.42; N 10.57010
found: C 31.85;H 3.56; N 10.73010
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UV spectrum: }.max213 and 282 nm (log e 3.97 and 4.0), J..min243 nm (log e 3.22). IR
spectrum: VmaX3312, 3177br, 3040br, 2947, 1707br, 1662br, 1652sh, 1614, 1457, 1417, and
1025 cm-lo lH-NMR spectrum: ~H 11.72 br (IH, s, 3-NH), 8.01 (IH, s, 6-H), 5.05 (IH,
d, 2'-OH; JOH.2' 4.98 Hz), 4.72 (IH, t, 3'-OH; JOH.~' 5.28 Hz), 4.05-3.14 (5H, m, l'-H2'
2'-H, 3'-H2). l3C-NMR spectrum: ~c 159.59 (C-4, s), 150.29 (C-2, s), 146.48 (C-6, dl,
93.56 (C-5, s), 68.61 (C-2', dl, 63.45 (C-3', t), 51.41 (C-1', t).
(R,S )-2 -Hyd roxymethy 1-tetrah yd ro-oxazo 10[3,2-c ]pyrimidine-5, 7-(4H,6H)-
-dione (V)
a) To a solution of (R,S)-1-(2,3-dihydroxypropyl)-5-bromouracil (X) (200 mg,
0.75 mmol) in anhydrous DMF (5 ml), dried KCN (54 mg, 0.83 mmol) was added.
The mixture was stirred at room temperature for 48 h. The precipitate was then
filtered off and the filtrate evaporated to dryness under reduced pressure. The
residue was dissolved in MeOH and filtered through ashort alumina (neutral)
column. It afforded the product V (91 mg, 66010), m. p. 243-244 =c (from MeOH),
RF ca. 0.38.
AnaL C7H8N204 (184.17) calc'd.: C 45.65; H 4.39; N 15.21010
found: C 45.82; H 4.60; N 15.47010
UV spectrum: }.max214sh and 253 nm (log e 3.36 and 3.83), J..m1n227 nm (log e 3.24).
IR spectrum: VmaX3330br, 3030br, 1720br, 1650br, 1480br, 1465sh, 1405, and 780 cm'".
lH-NMR spectrum: ~H 10.84br (IH, s, 6-NH), 5.26 (IH, t, l'-OH; JOH•1' 5.57 Hz), 5.16-
4.92 (IH, m, 2-H; obscured by those of 8-H), 4.91 (IH, d, 8-H; J8.6 1.47 Hz), 4.03 (IH,
dxd, 3-Ha; J a,b 9.96 and Ja•2 8.5 Hz), 3.81 (IH, dxd, 3-Hb; s,.a 9.96 and Jb•2 6.45 Hz),
3.79-3.44 (2H, m, l'-H2 obscured by those of 3-Hb). l3C-NMR spectrum: ~c 164.73
(C-7, s), 162.81 (C-5, s), 147.86 (C-8a, s), 82.62 (C-8, dl, 74.55 (C-2, dl, 61.01 (CH20H, tj,
43.23 (C-3, tj.
b) A solution of (R,S)-6-cyano-1-(2,3-dihydroxypropyl)-uracil (XI) (22 mg, 0.104
mmol) in anhydrous DMF (0.3 ml) was treated with freshly prepared t-BuOK
[K (10.2 mg) in t-BuOH (1.4 ml)] and stirred at room temperature for 90 min.
The mixture was neutralized with 1 mol dm? HCI, the solvent removed under
reduced pressure, and the residue subjected to the preparative TLC. It afforded
the product V (7.8 mg, 41010), m. p. 243-244 CC (from MeOH), Rp ca. 0.38, identical
(IR and lH-NMR) to that described in section al.
c) A solution of (R,S)-6-cyano-1(2,3-dihydroxypropyl)-uracil (XI) (19.2 mg, 0.09
mmol) in DMSO (2.5 ml) was heated at 40 CC for 73 h. The solvent was then
removed under reduced pressure and the residue subjected to the preparative TLC.
It gave the product V (11 mg, 67010), m. p. 242-244 aC (from MeOH), R. 0.38,
identical (IR and lH-NMR spectra) to that obtained in section al.
(R,S)-5-Bromo-(2,3-0-isopropylidene-2,3-dihydroxypropyl)-'uracil (XrII)
To a solution of 5-bromouracil (603 mg, 3 mmol) in anhydrous DMF (8 ml),
NaH (132 mg) was added. The mixture was stirred at room temperature for 1 h
and then treated with 1-0-p-tolylsulphonyl-2,3-0-isopropylidene-glycerol (512 mg,
2 mmol). This mixture was stirred at 100aC for 17 h, cooled and filtered through
a Celite column. The filtrate was evaporated to dryness under reduced press ure
and the residue tri tura ted with hot CHCI3. The chloroform solution was concentra-
ted to a small volume and subjected to the preparative TLC (developed in ether;
recovery with EtOH). It afforded the product XIII in 40.5010 yieid, m. p. 181-182 aC
(from CHCIs), RF ca. 0.42 (ether).
AnaL Cl0H1SBrN204 (305.14) calc'd.: C 39.36; H 4.29; N 9.18010
found: C 39.57; H 4.20; N 9.09010
UV spectrum: J.max213 and 283 nm (log e 3.87 and 3.90), J..m1n242 nm (log
e 3.09). IR spectrum: VmaX3420br, 3165br, 3100, 3035br, 2990, 2930, 1715br, 1680sh,
1675br, 1650sh, 1615, 1455sh, 1445, and 1420 cm-lo lH NMR spectrum (in CDCls):
~H 7.68 (IH, s, 6-H), 4.41-4.29 (IH, m, 2'-H), 4.12 (IH, dxd, 3'-Ha; s., 8.79 Ja.2' 6.15
Hz), 4.06 (IH, dxd, r-n.. J a,b 14.06, Ja.2' 2.64 Hz), 3.75 (IH, dxd, l'-Hb; s., 14.06,
Jb.2, 6.45 Hz), 3.70 (IH, dxd, 3'-Hb; s., 8.79, Jb.2, 5.86 Hz), 1.44 and 1.35 (each 3H,
2s, C(Mel2). l3C-NMR spectrum: ~c 159.59 (C-4, sl, 150.57 (C-2, s), 145.85 (C-6, dl,
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108.72 (O-C-O, s), 94.24 (C-5, s), 73.05 (C-2', d), 65.74 (C-3', t), 49.56 (C-1', t),
26.31 and 25.00 (each (CH3h-C, 2q).
(R,S)-6-Cyano-l-(2 ,3-O-isopropy lidene-2 ,3-dih ydroxypropy l)-uracil (XII)
To a solution of (R,S)-5-bromo-1-(2,3-0-isopropylidene-2,3-dihydroxypropyl)-
uracil (XIII) (140 mg, 0.457 mmol) in anhydrous DMF (1.25 ml), dried NaCN (26.9
mg, 0.549 mmol) was added and stirred at room temperature for 24 h. The mixture
was diluted with water (0.28 ml) and then neutralized with 1 mol dm'" HCI (0.14
ml) under nitrogen atmospehere within 2 min. The solvent was removed under
reduced pressure and the product XII crysta1lized from CHCI3-n-hexane (65 mg,
55010), m. p. 188-189°C (from CHCI3), RF ca. 0.35 (CH2Ch-MeOH, 20 : 1).
AnaI. CllH13N304(251.23)calc'd.: C 52.59; H 5.21; N 16.73010
found: C 52.31; H 5.23; N 16.46010
UV spectrum: }'m.x 203 and 290 nm (log e 4.01 and 3.99), Amin 235 nm (log e 3.29).
IR spectrum: Ym ax 3435br, 3165, 3085, 3055, 2995, 2245, 1720sh, InObr, 1665, 1595,
1465, and 1410 cm-i. lH-NMR spectrum (CDCI3): ~H 9.55 (IH, s, 3-NH), 6.26 (IH, s,
5-H), 4.45-4.23 (IH, m, 2'-H), 4.13 (IH, dxd, l'-Ha; s., 14.40, J a,2' 4.64 Hz) 4.07
(IH, dxd, 3'-Ha; J a ,b 8.79, J a ,2' 6.35 Hz), 3.79 (IH, dxd, l'-Hb; Jb.a 14.16, Jb.2' 8.55 Hz),
3.75 (IH, dxd, 3'-Hb; s,.a 8.79, Jb.2' 5.62 Hz), 1.51 and 1.34 (each 3H, 2s, C(CH3h).
l3C-NMR spectrum (CDCI3): ~C 169.49 (C-4, s), 159.85 (C-2, s), 129.89 (C-6, s), 111.42
(CN, 2JCH), 111.42 (C-5, d), 110.76 (O-C-O, s), 72.80 (C-2', d), 66.58 (C-3:, t), 50.58
(C-1', t), 26.21 and 25.09 (each (CH3hC, 2q).
(R,S)-6-Cyano-l-(2,3-dihydroxypropyl)uracil (XI)
A solution of (R,S)-6-cyano-I-(2,3-0-isopropylidene-2,3-dihydroxypropyl)uracil
(XII) (30 mg, 0.119 mmol) in 80% AcOH (4 ml) was stirred at room temperature
for 20 h. The solvent was removed azeotropically with EtOH under reduced pressure.
The residue recrystallized from MeOH yielding the product XI (24 mg, 97010), m. p.
161-162°C, RF ca. 0.76.
AnaI. CSH9N304(211.18)calc'd.: C 45.50; H 4.30; N 19.90010
found: C 45.28; H 4.28; N 20.180/0
UV spectrum: J.m>. 202 and 293 nm (log s 3.49 and 3.34), Amin 234 nm (log e 2.69).
IR spectrum: YmOX 3400br, 3160br, 3080, 3040br, 2950, 2250, 1737sh, 1710sh, 1708b:r,
1685sh, 1658sh, 1598, 1470, and 1420 cm-lo lH-NMR spectrum: ~H 11.75br (IH, s,
3-NH), 6.53 (IH, s, 5-H), 5.25 (IH, d, 2'-OH; JOH.2' 4.03 Hz), 4.77 br (IH, s, 3'-OH),
4.13-3.16 (5H, m, l'-H2, 2'-H, 3'-H2)' l3C-NMR spectrum: ~c 161.27 (C-4, s), 149.40
(C-2, s), 129.51 (C-6, s), 111.76 (CN, 2JCH), 110.40 (C-5, d), 67.74 (C-2', d), 63.37 (C-3',
t), 50.77 (C-1', t).
(R)-2,3-Dihydro-trityloxymethyl-7H-oxazolo[3,2-a]pyrimidin-7-one (XVI)
To a solution of (S)-1-(2-mesyloxy-3-trityloxypropyl)-uracil (S)-(XV) (270 mg,
0.533 mmol) , prepared from (S)-I-(3-0-trityl-2,3-dihydroxypropyl)uracil according
to the procedure described by Holy-š, in DMF (5 ml), 1,8 diazabicyclo[5.4.0]-undecen-
-7-ene (0.085 ml, 0.57 mmol) was added. The mixture was stirred at room tempe-
rature for 15 h. The solvent was then removed under reduced pressure. The pre-
parative TLC (CH2Ch-MeOH, 9: 1) afforded the product XVI(209.8 mg, 96%),
m. p. 180-181°C (from MeOH-CHCI3-n-hexane), RF ca. 0.42 (in CH2CI2-MeOH,
9 : 1), [a1020 + 16° (c 2, CHCI3), identical to that described earlter>.
(R)-5-Bromo-l-(2,3-dihydroxypropyl)uracil (R)-(XVII)
A solution of (R)-1-(2,3-dihydroxypropyl)uracil13.l7 (R)-(VI), [aJn26 + 76° (c 1,
EtOR), (19 mg, 0.102 mmol) in anhydrous EtOH (5 ml) was treated with bromine
(0.011ml, 0.2 mmol) dissolved in CH2Cl2 (1.55 ml) and worked up as described for
the preparation of the (R,S)-product (R,S)-X. Recrysta1lization from MeOH yielded
R-XVII (22.5 mg, 850/0),-rn, p. 208-2100C, RF ca. 0.71, [a]o25 + 43.5° (c 2, DMF).
IR and iH NMR spectra were identical with those described for (R,S)-X.
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(S)-5-Bromo-l-(2,3-dihydroxypropyl)uracil (S)-(XVII)
(S)-1-(2,3-Dihydroxypropyl)uracil (S)-(VI), [a]n35 -76° (c 1, EtOH) (Lit. 15
[a]n25 - 22.3° (c 1, H20», (116.7 mg, 0.627 mmol), prepared from (S)-1-(2,3-0-iso-
propylidene-2,3-dihydroxypropyl)uracil13•14 by treatment in boiling 80% AcOH, was
dissolved in anhydrous EtOH (28 ml) and treated with a solution of bromine (0.065
ml, 1.19 mmol) in CH2Ch (9.3 ml) and worked up as already described. Recrystalli-
zation from MeOH afforded the (S)-enantiomer XVII (129.6 mg, 78%), m. p. 208-
-2100C, Rp ca. 0.71, [a]25n - 44° (c 2, DMF).
IR and lH-NMR spectra were identical with those record ed for (R,S)-X and
the (R)-enantiomer XVII.
(R)-2 -Hyd roxymeth y l- tetmh ydTO-oxazo lo[3 ,2-c]pyrimidine-5, 7-(4H,6H )-dione
(R)-(V)
A solution of (R)-5-bromo-1-(2,3-dihydroxypropyl)uracil (R)-(XVIJ) (24 mg, 0.091
mmol) in anhydrous DMF (1 ml) was treated with dried KCN (6.5 mg, 0.1 mmol)
and worked up as described for the preparation of (R,S)-V. Recrystallization from
MeOH gave the (R)-enantiomer V (8.3 mg, 60%), m. p. 242-244 °C, RF ca. 0.38,
[a]n26 - 13° (c 2, EtOH).
IR spectrum was identical with that described for (R,S)-V.
(S)-2-Hydroxymethyl- tetrahydro-oxazolo[3,2-c }pyrimidine-5, 7-(4H,6H)udione
(S)-(V)
A solution of (S)-5-bromo-1-(2,3-dihydroxypropyl)uracil (S)-(XVIJ) (57.5 mg,
0.22 mmol) in anhydrous DMF (2 ml) was treated with dried KCN (15.5 mg, 0.242
mmol) and worked up as already described. Recrystallization from MEOH afforded
the (S)-enantiomer V (24.3 mg, 610f0), m. p. 243-244 °C, RF ca. 0.38, [a]23 + 12° (c
2, EtOH).
IR and lH-NMR spectra were identical with those recorded for (R,S)-V and
the (R)-enantiomer V.
(R,S)-1-(2,3-0-Isopropylidene-2,3-dihydroxypropyl)-3-methyluracil (XX)
To a cooled (O °C) and freshly prepared solution of diazomethane [prepared
from N-nitrosotoluene-4-sulphomethylamide (1.07 g, 5 mrnol)] in ether (15 ml), a
solution of (R,S)-1-(2,3-0-isopropylidene-2,3-dihydroxypropyl)uracil4 (XIX) (594 mg,
2.63 mmol) in anhydrous MeOH (16 ml) was added dropwise. The mixture was than
kept at room temperature for 1 h and evaporated to dryness under reduced
pressure. The product XX crystallyzed from CHC13-n-hexane (555 mg, 88%), m. p.
114-115°C (from CHC13),RF ca. 0.80.
AnaL CllH16N204 (240.26) calc'd.: C 54.99; H 6.71; N 11.66%
found: C 54.61; H 6.80; N 11.54%
UV spectrum: }'m.x 210 and 265 nm (log e 4.09 and 4.17), }'min 233 nm (log e 3.50).
IR spectrum: Ym" 3355, 3085, 2985, 2955, 2945, 2910, 1715, 1695, 1695, 1665, 1660, 1630,
1465, 1450, 1440, and 1038 cm-I. lH-NMR spectrum: bH 7.29 (IH, d, 6-H; J6.5 8.06
Hz), 5.74 (IH, d, 5-H; J5.6 8.06 Hz), 4.56-4.28 (IH, m, 2'-H), 4.12 (IH, dxd, 3'-Ha; i.,
8.55, J a,2' 6.35 Hz), 4.11 (IH, dxd, l'-H.; J a.b 14.16, J a ,2' 2.69 Hz), 3.68 (IH, dxd, 3'-Hh;
Jb.a 8.55, Jb.2' 6.10 Hz), 3.68 (IH, dxd, l'-Hb; s.. 14.16, Jb.2' 6.84 Hz), 3.34 (3H, s,
N-CH3), 1.42 and 1.34 (each 3H, 2s, C(CH3l2). 13C-NMR spectrum: ac 162.42 (C-4, s),
151.35 (C-2, s), 144.58 (C-6, dl, 108.77 (O-C-O, s), 99.55 (C-5, dl, 73.14 (C-2, dl,
65.23 (C-3', t), 50.78 (C-1', t), 27.24 (N-CH3, q), 26.16 and 25.10 (each (CH3)2C,2q).
(R,S)-1-(2,3-Dihydroxypropyl)-3-methyluracil (XXI)
A solution of (R,S)-I-(2,3-0-isopropylidene-2,3-dihydroxypropyl)-3-methyluracil
(XX) (760 mg, 3.17 mmol) in 80% AcOH (250 ml) was stirred at room temperature
for 16 h. The solvent was removed azeotropically with EtOH under reduced pressure.
1-(2,3-DIHYDROXYPROPYL)URACIL DERIVATIVES 591
The residue crystallized from EtOH-Et20 yielding the product XXI (552 mg, 870/0),
m. p. 85-87 =c, Rp ca. 0.41.
AnaI. CSH12N204(200.2) calc'd.: C 47.99; H 6.04; N 14.00010
found: C 47.79; H 6.35; N 13.64010
UV spectrum: Amax 213 and 264 nm (log li 3.80 and 3.90), Ami. 2B3 nm (log li 3.18).
IR spectrum: VmaX 3470br, 3115, 3095, 2910, 1700br, 1665sh, 1558 1650sh, 1620, 1475sh,
1465, 1460sh, 1450sh, and 1410br cm-lo HI-NMR spectrum: c5H 7.26 (IH, d, 6-H);
h5 8.06 Hz), 5.75 (IH, d, 5-H; J5.6 8.06 Hz), 4.07-3.44 (5H, m, l'-H2, 2'-H, 3'-H2),
3.34 (3H, s, N-CHs), 2.92 (IH, d, 2'-OH; JOH•2' 4.64 Hz), 2.58 (IH, t, 3'-OH; JOH,s'6.1
Hz). 13C-NMR spectrum: c5c 162.61 (C-4, s), 151.21 (C-2, s), 145.12 (C-6, d), 98.92
(C-5, d), 68.81 (C-2', d), 63.54 (C-3', t), 52.19 (C-1', t), 27.09 (CHsN, q).
(R,S)-5-Bromo-l-(2,3-dihydroxypropyl)-3-methyluracil (XVIII)
To a solution of (R,S)-1-(2,3-dihydroxypropyl)-3-methyluracil (XXI) (897 mg,
4.4 mrnol) in CH2C12 (195 ml), bromine (0.45 ml, 8.2 mmol) in CH2Cb (64 ml) was
added dropwise. The mixture was then stirred at room temperature for 20 h and
evaporated to dryness und er reduced pressure. The residue was crystallized from
EtOH, yielding the product XVIII (825 mg, 660/0), m. p. 180-182°C (from EtOH),
Rp ca. 0.71.
AnaI. CsHllBrN204 (279.11) calc'd.: C 34.42; H 3.97; N 10.04010
found: C 34.46; H 4.21; N 9.84010
UV spectrum: Amax 213 and 282 nm (log li 3.91 and 3.94), Ami. 244 nm (log li 3.94).
IR spectrum: Vmax 3520, 3455br, 3335sh, 3055, 2955, 2925, 1690, 1645br, 1460br, 1440,
1430, 1240, and 1020 cm-I. IH-NMR spectrum: c5H 8.90 (IH, s, 6-H), 3.22 (3H, s,
N-CHs). 13C-NMR spectrum: oc 159.00 (C-4, s), 150.43 (C-2, s), 144.77 (C-6, d), 92.93
(C-5, s), 68.61 (C-2', d), 63.50 (C-3', t), 52.58 (C-1', t), 28.67 (CHsN, q).
(R,S)-2-Hydroxymethyl-6-methyl-tetrahydro-oxazolo[3,2-cJ-pyrimidine-
-5,7-(4H,6H)-dione (XXII)
To a solution of (R,S)-2-hydroxymethyl derivative (R,S)-V (23 mg, 0.12 mrnol)
in anhydrous MeOH (19 ml), a freshly prepared solution of diazomethane [prepared
from N-nitrosotoluene-4-sulphomethylamide (214 mg, 1 mmol)] in ether (3 ml) was
added. The mixture was set aside at room temperature for 4 h and then concen-
trated to a smaller (7 ml) volume. On tri tura ti on with n-hexane, the crystal1ine
product XXII was obtained (19.4 mg, 79010), m. p. 204-205 °C (from MeOH),
Rp ca. 0.5.
AnaI. CSH10N204 (198.18) calc'd.: C 48.48; H 5.09; N 14.14010
found: C 48.64; H 5.28; N 14.23010
UV spectrum: Amax 204 and 253 nm (log li 3.89 and 4.08), Ami. 227 nm (log li 3.51).
IR spectrum: VmaX 3292br, 3107, 3017, 2937, 1727br, 1687sh, 1652br, 1617, 1592, 1482br,
1460, and 1442br cm-I. IH NMR spectrum: c5H 5.27 (IH, t, l'-OH; JOH.l' 5.57 Hz),
5.18-4.93 (IH, m, 2-H), 5.08 (IH, s, 8-H), 4.10 (IH, dxd, 3-Ha; i., 9.96, Ja, 2 8.50 Hz),
3.84 (IH, dxd, 3-Hb; s., 9.96, h2 6.45 Hz), 3.86-3.51 (2H, m, l'-H2; obscured by
those of 3-Hb), 3.22 (3H, s, N-CHs). 13C-NMR spectrum: c5c 163.54 (C-7, s) 161.01
(C-5, s), 148.25 (C-8a, s), 82.40 (C-8, dj, 74.21 (C-2, d), 60.95 (CH20H, t), 44.08
(C-3, tj, 26.75 (CHs-N, q).
(R)-2-Hydroxymethyl-6-methyl-tetrahydro-oxazolo[3,2-cJ-pyrimidine-
-5,7-(4H,6H)-dione (R)-(XXII)
A solution of (R)-2-hydroxymethyl-tetrahydro-oxazolo-[3,2-c]pyrimidine-5,7-
-(4H,6H)-dione (R)-(V) (32.7 mg, 0.178 mmol) in MeOH (17.5 ml) was treated with
a freshly prepared solution of diazomethane [prepared from N-nitrosotoluene-4-
-sulphomethylamide (214 mg, 1 mmol)] in Et20 (3 ml) and worked up as described
for the preparation of (R,S)-XXII. The preparative TLC afforded the crystalline
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product (R)-XXII (27.5 mg, 78010),m. p. 203-2050C (from MeOH) RF ca. 0.5, x[aJn22.S
-49.5° (c 1, MeOH). '
IR spectrum was identical with that described for (R,S)-XXII.
(S)-2-Hydroxymethyl-6-methyl-tetrahydro-oxazolo[3,2-c]-pyrimidine-
-5,7-(4H,6H)-dione (S)-(XXII)
A solution of (Sj-ž-hydroxymethyl- tetrahydroxo-oxazo1o- [3,2-c]pyrimidine-5, 7-
-(4H,6H)-dione (S)-(V) (45.5 mg, 0.247 mmo1) in MeOH (24.2 ml) was treated with
a freshly prepared solution of diazomethane [prepared from N-nitrosoto1uene-4-
-sulphomethylamide (214 mg, 1 mmo1)] in Et20 (3 ml) as a1ready described. Pre-
parative TLC afforded the product (S)-XXII (36.7 mg, 750/0),m. p. 204-205 °c (from
MeOH), Rp ca. 0.5, [a]o23 +49.5° (c 1, MeOH).
IR spectrum was identical to that recorded for (R,S)-XXII and the (S)-
-enantiomer (S)-XXII.
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SAŽETAK
Anti-ciklizacije enantiomernih 1-(2,3-dihidroksipropil)-uracil-derivata
V. Škarić i B. Kašnar
Opisane su sinteze i enantiomerne značajke 2-hidroksimetil-tetrahidro-oksazolo-
[3,2-c]pirimidin-5,7-(4H,6H)-diona(V). Metiliranja tih optički aktivnih bicikličkih spo-
jeva s pomoću diazometana daju (R)-2-hidroksimetil-6-metil-tetrahidro-oksazolo[3,2-
-c]pirimidin-5,7-(4H,6H)-dion (R)-(XXII), odnosno njegov (S)-enantiomer (S)-(XXII).
Priprava bicikličkih enantiomera (R)-V i (S)-V iz odgovarajućih 5-bromo-l-(2,3-
-dihidroksipropil)uracila (R)-(XVII) i (S)-(XVII) vrši se u reakciji sa KCN u DMF.
Pritom je utvrđeno da ta transformacija slijedi nastajanje (R,S)-6-cijano-1-(2,3-
-dihidroksipropil)uracila (XI) i njegovu anti-ciklizaciju u DMSO pri 40 cC.
